This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GTA-Glyceryltriacetate for Canavan Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2006 by Sheba Medical Center.
Recruitment status was:  Active, not recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: January 15, 2006
Last updated: August 11, 2006
Last verified: August 2006
January 15, 2006
August 11, 2006
January 2006
Not Provided
  • All primary outcome will be evaluated 4 months following the initiation of treatment:
  • Neurological Status
  • Brain Imaging: MRI & MRS
  • NAA Levels in Urine
  • Ophthalmologic Examination
Same as current
Complete list of historical versions of study NCT00278707 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
GTA-Glyceryltriacetate for Canavan Disease
Phase 1 Treatment With GTA in Two Infant With Canavan Disease
The purpose of this study is to determine whether oral supplementation of glyceryl triacetate improves the clinical prognosis of Canavan Disease.

Canavan Disease is caused by a deficiency in the enzyme named Aspartoacylase (ASPA). This disease is a devastating, progressive disease with no available treatment. As a result of the ASPA deficiency, there are high levels of N-acetylaspartate (NAA) and low levels of L-aspartate and acetate.

We hypothesize that one of the functions of ASPA is to provide sufficient levels of acetate for CNS myelinization. For this reason, we offer to supplement acetate levels by the oral administration of glyceryl triacetate (GTA). Such treatment must be offered to patients before the age of 18 months, prior to the termination of CNS myelinization.

  1. Two patients, aged less than 15 months, will receive daily doses of oral GTA
  2. The daily dose will be increased incrementally until the maintenance dose is reached. This will be done under close monitoring of the patients, including periodic blood gas sampling.
  3. GTA has not been shown to cause any known toxicity, according to the Cosmetic Ingredient Review Expert Panel (Fiume, 2003).
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Infantile Canavan Disease
  • Deficiency Disease, Aspartoacylase
Drug: GTA: Glyceryltriacetate
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
July 2006
Not Provided

Inclusion Criteria:

  • Age below 15 months
  • Biochemically diagnosed with Canavan Disease

Exclusion Criteria:

Sexes Eligible for Study: All
up to 15 Months   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Sheba Medical Center
Not Provided
Principal Investigator: Yair Anikster, MD PI Director Metabolic Disease Unit
Sheba Medical Center
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP